8-K: Intensity Therapeutics Resumes Key Cancer Trials, Reports Q2 Results

Intensity Therapeutics announced the resumption of enrollment in its Phase 3 soft tissue sarcoma study and restarted patient treatment in its Phase 2 triple-negative breast cancer trial, alongside its second quarter 2026 financial results.

Summary

• Intensity Therapeutics reported its financial results for the second quarter ended June 30, 2026.
• The company has initiated activities to resume enrollment in a limited number of U.S. sites for the Phase 3 INVINCIBLE-3 Study for soft tissue sarcoma by the third quarter of 2026, following a pause due to funding constraints.
• Patient treatment has restarted in the Phase 2 INVINCIBLE-4 Study for triple-negative breast cancer (TNBC).
• As of June 30, 2026, the company had $9.5 million in cash and cash equivalents.
• Research and development expenses were $1.8 million for Q2 2026, an increase from $1.5 million in Q2 2025, primarily due to resuming INVINCIBLE-3 Study activities.
• General and administrative expenses were $1.3 million for Q2 2026, slightly up from $1.2 million in Q2 2025.
• The net loss for Q2 2026 was $3.0 million, compared to a net loss of $2.5 million in Q2 2025.
• The company raised $1.6 million in net proceeds under its $60 million at-the-market (ATM) facility during Q2 2026 and an additional $1.3 million subsequent to quarter-end.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with positive steps in clinical trial restarts and preliminary data, balanced by ongoing funding constraints and net losses.

Positives

• Resumption of enrollment activities for the Phase 3 INVINCIBLE-3 Study in soft tissue sarcoma by Q3 2026.
• Restart of patient treatment in the Phase 2 INVINCIBLE-4 Study for TNBC.
• Preliminary data from INVINCIBLE-4 Study shows a 71% pathological complete response (pCR) rate in Cohort A (INT230-6 + SOC) and a 42% pCR in Cohort B (SOC alone).
• A 44% reduction in grade 3 adverse events was observed in Cohort A compared to Cohort B in the INVINCIBLE-4 Study.
• Fewer immune-related adverse events were noted when INT230-6 was added prior to immunochemotherapy in INVINCIBLE-4.
• Raised $1.6 million in net proceeds in Q2 2026 and an additional $1.3 million post-quarter end under the ATM facility.
• Increased business development activities, including meetings with potential strategic partners at BIO International Conference.

Negatives

• Net loss of $3.0 million for the second quarter of 2026.
• Cash and cash equivalents decreased to $9.5 million as of June 30, 2026, from $11.9 million at the end of 2025.
• Research and development expenses increased in Q2 2026 compared to Q2 2025, impacting the net loss.
• The company previously paused new site activations and patient enrollment in March 2025 due to funding constraints.
• The company previously paused new patient enrollment in September 2025 due to localized skin irritation concerns in INVINCIBLE-4 Study.

Risks

• The company may need to raise additional funding before generating revenues from product sales.
• Product candidates that appear promising in early trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• The company's ability to maintain and establish collaborations or obtain additional funding is uncertain.
• Potential inability to satisfy Nasdaq Capital Market requirements for continued listing and risk of delisting.
• Risks related to the initiation, timing, progress, and results of future preclinical studies and clinical trials.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals.
• The company does not undertake any obligation to update forward-looking statements.

Future Outlook

The company is pursuing potential partnerships to advance its programs and expects to continue discussions in the second half of 2026. Site activation and patient enrollment rates are expected to increase as sufficient funding is obtained. The company aims to complete enrollment in the INVINCIBLE-4 Study by the end of 2027.

Management Comments

• We are pleased that the capital raised in 2025 and to date in 2026 provides the resources to reinitiate the Phase 3 INVINCIBLE-3 Study.
• In the Phase 2 INVINCIBLE-4 Study, early data show potential for an improvement in the pCR rate with a reduction in the number of grade 3 adverse events including immune-related adverse events.
• These preliminary findings are encouraging, and we are excited that investigators have restarted treatment in patients in Switzerland.
• We look forward to enrolling new patients in this study in France now that sites are being activated.
• We continue to pursue potential partnerships to advance our programs, and held meetings with potential strategic partners at the BIO International Conference in late June.
• While early, we are pleased with the interest expressed in our science and clinical trials, and we expect to continue discussions in the second half of 2026.

Industry Context

StockSavvy.ai notes that Intensity Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, where progress in clinical trials and securing funding are critical determinants of success. The company's focus on intratumoral cancer therapies positions it within a growing area of oncology research aiming for more targeted and potentially less toxic treatments.

Stakeholder Impact

• Shareholders: The resumption of trials and positive preliminary data may be viewed positively, but ongoing funding needs and net losses present risks. The ATM facility allows for ongoing capital infusion.
• Patients: Restarting enrollment in critical trials (INVINCIBLE-3 and INVINCIBLE-4) offers potential new treatment options and continued access to investigational therapies.
• Employees: Increased R&D activities and business development may lead to expanded operational needs and potential growth opportunities.
• Creditors: The company's cash position and ongoing capital raises will be monitored for its ability to meet financial obligations.

Next Steps

• Resume enrollment in a limited number of U.S. sites for the Phase 3 INVINCIBLE-3 Study by the third quarter of 2026.
• Complete enrollment in the Phase 2 INVINCIBLE-4 Study by the end of 2027.
• Continue pursuing potential partnerships and discussions in the second half of 2026.
• Submit documentation for restarting INVINCIBLE-3 Study in the EU.
• Open additional sites in France for the INVINCIBLE-4 Study.

Key Dates

Recommendation

The company is making progress in its clinical programs with encouraging preliminary data, but faces significant funding challenges and continued net losses. The resumption of trials is positive, but the path to commercialization remains long and uncertain, warranting a hold recommendation until further de-risking events occur.

Keywords

Intensity Therapeutics, INT230-6, soft tissue sarcoma, triple negative breast cancer, clinical trials, Phase 3, Phase 2, biotechnology